Circulation: Heart Failure

SEPTEMBER 12, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. mL/kg per min lower peak VO2(β, −2.35±0.19;P<0.001).

Biomarkers 40

Biomarkers Obesity Exercise Preserved Ejection Fraction 40

Circulation

NOVEMBER 11, 2024

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. in HFD/L-NAME vs E/A=1.4 ± 0.02

Hypertension 40

Hypertension Preserved Ejection Fraction Blood Pressure Obesity 40

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

European Journal of Heart Failure

NOVEMBER 19, 2024

Muscle quality and cardiac function in heart failure with preserved ejection fraction (HFpEF) during exercise. Cardiac output (CO) was measured via the open-circuit acetylene wash-in technique, heart rate by electrocardiogram, and cardiac power output (CPO) was calculated.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiac Function Exercise Heart Failure 40

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

Journal of the American Heart Association

JANUARY 23, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.

Heart Failure 45

Heart Failure Preserved Ejection Fraction Obesity Outcomes 45

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. It also lowered their systolic blood pressure and waist circumference.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Circulation

NOVEMBER 11, 2024

We excluded articles related to acute decompensated HF and HF with preserved ejection fraction. to -0.16, p=0.00) (Figure 1B), were associated with a reduction in systolic blood pressure (MD = -0.32, 95% CI: -0.51 The primary outcome was the change in NYHA functional class (FC). to 0.36, p=0.06) (Figure 1D).

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Disease Preserved Ejection Fraction 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

DAIC

APRIL 9, 2024

There were also no adverse events related to low ejection fraction (a measure of how well the heart pumps blood) and no adverse effects on blood pressure or heart rate. Maron said that a larger phase 3 trial would help shed light on the magnitude of the drug’s potential benefits.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Ndumele provided an in-depth analysis of cardiac biomarkers and their role in cardiovascular risk prediction and heart failure (HF) management at the 19th Annual CMHC. Biomarker-Based HF Prediction: Combined biomarker and imaging assessments provide the highest accuracy in predicting heart failure risk.

CME 103

CME Obesity Heart Failure Biomarkers 103